Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Articles|September 18, 2026
What CRISPR Gene Therapy Means for HAE: FAQ on This 1-Time Treatment
Author(s)Chelsie Derman
Fact checked by: Tim Smith
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
Advertisement
Advertisement
On September 8, 2026, the
Related to this article
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.
Advertisement
Advertisement